<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="905">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149378</url>
  </required_header>
  <id_info>
    <org_study_id>SZRTALL01</org_study_id>
    <nct_id>NCT05149378</nct_id>
  </id_info>
  <brief_title>Venetoclax Based Regimen for R/R T-ALL</brief_title>
  <official_title>Venetoclax Based Regimen for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jining Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second People's Hospital of Huai'an</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Bengbu Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern Jiangsu Province People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Nantong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Suzhou Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the therapeutic efficacy and side effect of venetoclax based&#xD;
      regimen for relapsed or refractroy T cell acute lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 21 days)</time_frame>
    <description>The overall response (complete remission, complete remission with incomplete blood count recovery) rate achieved after one or two courses (21 days) induction therapy by venetoclax combined azacitidine regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Remission Rate (CRR)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 21 days)</time_frame>
    <description>The complete remission rate achieved after one or two courses (21 days) induction therapy by venetoclax combined azacitidine regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survial (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>It is measured from the date of entry into this trial to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>It is measured from the date of entry into this trial to the date of progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in hematological system</measure>
    <time_frame>1 month</time_frame>
    <description>Record of adverse events in hematological system during and after designed venetoclax combined azacitidine regimen induction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in other organs or systems</measure>
    <time_frame>1 month</time_frame>
    <description>Record of adverse events in other organs or systmes during and after designed venetoclax combined azacitidine regimen induction.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Acute T-Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Venetclax combined with azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relapsed or refractroy acute lymphoblastic leukemia patients reveive venetclax combined with azacitidine regimen treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax combined with azacitidine regimen</intervention_name>
    <description>Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 .</description>
    <arm_group_label>Venetclax combined with azacitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged ≥ 15 and ≤ 65 years.&#xD;
&#xD;
          2. Patients diagnosed with T-ALL/LBL according to 2017 WHO lymphoid malignant disease&#xD;
             diagnosis standard.&#xD;
&#xD;
          3. Patients with T-ALL/LBL must meet one of the following criteria, A or B.&#xD;
&#xD;
             A: Refractory T-ALL/LBL disease was defined as follows: Failure to achieve CR at the&#xD;
             end of induction.&#xD;
&#xD;
             B: Relapsed T-ALL/LBL disease was defined as follows: Reappearance of blasts in the&#xD;
             blood or bone marrow (&gt;5%) or in any extramedullary site after a CR.&#xD;
&#xD;
          4. ECOG performance status score less than 3.&#xD;
&#xD;
          5. Expected survival time &gt;3 months.&#xD;
&#xD;
          6. Patients without serious heart, lung, liver, or kidney disease.&#xD;
&#xD;
          7. Ability to understand and voluntarily provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are allergic to the study drug or drugs with similar chemical structures.&#xD;
&#xD;
          2. Pregnant or lactating women, and women of childbearing age who do not want to practice&#xD;
             effective methods of contraception.&#xD;
&#xD;
          3. Active infection.&#xD;
&#xD;
          4. Active bleeding.&#xD;
&#xD;
          5. Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a&#xD;
             medical history within one year before enrollment.&#xD;
&#xD;
          6. Patients with mental disorders or other conditions whereby informed consent cannot be&#xD;
             obtained and where the requirements of the study treatment and procedures cannot be&#xD;
             met.&#xD;
&#xD;
          7. Liver function abnormalities (total bilirubin &gt; 1.5 times the upper limit of the&#xD;
             normal range, ALT/AST &gt; 2.5 times the upper limit of the normal range or patients with&#xD;
             liver involvement whose ALT/AST &gt; 1.5 times the upper limit of the normal range), or&#xD;
             renal anomalies (serum creatinine &gt; 1.5 times the upper limit of the normal value).&#xD;
&#xD;
          8. Patients with a history of clinically significant QTc interval prolongation (male &gt;&#xD;
             450 ms; female &gt; 470 ms), ventricular heart tachycardia and atrial fibrillation,&#xD;
             II-degree heart block, myocardial infarction attack within one year before enrollment,&#xD;
             and congestive heart failure, and patients with coronary heart disease who have&#xD;
             clinical symptoms and requiring drug treatment.&#xD;
&#xD;
          9. Surgery on the main organs within the past six weeks.&#xD;
&#xD;
         10. Drug abuse or long-term alcohol abuse that would affect the evaluation results.&#xD;
&#xD;
         11. Patients who have received organ transplants (excepting bone marrow transplantation).&#xD;
&#xD;
         12. Patients not suitable for the study according to the investigator's assessment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sheng-Li Xue, M.D.</last_name>
    <phone>008651267781139</phone>
    <email>slxue@suda.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng-Li Xue, M.D.</last_name>
      <phone>+8651267781139</phone>
      <email>slxue@suda.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>venetoclax</keyword>
  <keyword>relapse</keyword>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

